China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.
You may also be interested in...
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.
'We've got be sure that companies can continue to get ingredients for their products," says CRN CEO Steve Mister, Concern supplies from India, which is a week into a a three-week nationwide lockdown, and other potential supply chain problems were noted by CRN members in a survey it conducted to help USDA gauge global food and nutrition ingredient supply chains during the pandemic.